Home Site Map Chinese
Dr. Ching-Shih Chen
Distinguished Research Fellow
Institute of Biological Chemistry, Academia Sinica
128, Academia Road Sec. 2, Nankang, Taipei 115, Taiwan
TEL: +886-2-27855696 ext. 3060
FAX: +886-2-27889759

Our laboratory is taking a multidisciplinary approach to identify novel therapeutic targets for drug discovery, especially those involved in the phenotypic adaptation of cancer cells to tumor microenvironment. Our basic science findings will be further translated into the design of new therapeutic agents and/or strategies for cancer treatment. Our current research consists of the following themes.
        1. Communications between KRAS mutant and wild type colorectal cancer cells through paracrine signaling to confer drug resistance.
        2. Identification of a novel KRAS regulatory loop in pancreatic cancer cells.
        3. Role of pancreatic stellate cells in pancreatic tumor progression and metastasis.
        4. Cancer-induced cachexia (communications between tumors and muscle)
        5. Tumor metabolism

- 1985 Ph.D., Pharmaceutical Biochemistry, University of Wisconsin
- 1980 M.S., Biochemistry, National Taiwan University
- 1978 B.S., Agricultural Chemistry, National Taiwan University

2018,02 - 2021,01 Distinguished Professor and Chair, Center of New Drug Development, Institute of New Drug Development, China Medical University (Secondment)
2014,08 - present Distinguished Research Fellow, Institute of Biological Chemistry, Academia Sinica
2001 - present Professor, Medicinal Chemistry and Internal Medicine, The Ohio State University
2014,08 - 2017,08 Director, Institute of Biological Chemistry, Academia Sinica
1998 - 2001 Professor, Pharmaceutical Sciences, University of Kentucky
1995 - 1998 Associate Professor, Pharmaceutical Sciences, University of Kentucky
1991 - 1995 Associate Professor, Medicinal Chemistry & Pharmacognosy, University of Rhode Island
1987 - 1991 Assistant Professor, Medicinal Chemistry & Pharmacognosy, University of Rhode Island

    Publications List
Targeting breast cancer stem cells by novel HDAC3-selective inhibitors.
H.-Y. Hsieh, H.-C. Chuang, F.-H. Shen, K. Detroja, L.-W. Hsin, and C.-S. Chen Eur. J. Med. Chem. (2017)
TGFb promotes Mesenchymal Phenotype of Pancreatic Cancer Cells through Epigenetic Activation of VAV1.
P.-H. Huang, P.-J. Lu, L-Y. Ding, P.-C. Chiu, W.-Y. Hsu, C.-S. Chen, C.-C. Tsao, B.-H. Chen, C.-T. Lee, Y.-S. Shan, and C.-S. Chen Oncogene (2017)
Non-epigenetic Function of HDAC8 in Regulating Breast Cancer Stem Cells by Maintaining Notch1 Protein Stability.
M.-W. Chao, P.-C. Chu, H.-C. Chuang, F.-H. Shen, C.-C. Chou, E.-C. Hsu, L. Himmel, H.-L. Huang, H.-J. Tu, S. Kulp, C.-M. Teng, C.-S. Chen Oncotarget (2016)
Regulation of Oncogenic KRAS Signaling via a Novel KRAS-ILK-hnRNPA1 Regulatory Loop in Pancreatic Cancer Cells.
P.-C. Chu, M.-C. Yang, S. K. Kulp, S. B. Salunke, Y.-S. Shan, C.-T. Lee, M.-D. Lai, L. A. Shirley, T. Bekaii-Saab, and C.-S. Chen Oncogene (2016)
Exploitation of the ability of γ-tocopherol to facilitate membrane co-localization of Akt and PHLPP1 to develop PHLPP1-targeted Akt inhibitors.
R. Yan, H.-C. Chuang, N. Kapuriya, C.-C. Chou, P.-T. Lai, H.-W. Chang, C.-N. Yang, S. K. Kulp, and C.-S. Chen J. Med. Chem. (2015)
Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia.
Tseng YC, Kulp SK, Lai IL, Hsu EC, He WA, Frankhouser DE, Yan PS, Mo X, Bloomston M, Lesinski GB, Marcucci G, Guttridge DC, Bekaii-Saab T, Chen CS J Natl Cancer Inst. (2015)
AMPK Reverses the Mesenchymal Phenotype of Cancer Cells by Targeting the Akt-MDM2-Foxo3a Signaling Axis.
C.C. Chou, K.H. Lee, I.L. Lai, D. Wang, X. Mo, S.K. Kulp, C.L. Shapiro, C.-S. Chen Cancer Res. (2014)
Suppression of prostate epithelial proliferation and intraprostatic pro-growth and survival signaling in transgenic mice by a novel energy restriction-mimetic agent.
L. D. Berman-Booty, P.-C. Chu, J. M. Thomas-Ahner, D. Wang, T. Yang, S. K. Clinton, S. K. Kulp, C.-S. Chen Cancer Prev. Res. (2013)
Vitamin E facilitates Akt dephosphorylation through membrane recruitment of PHLPP.
P.-H. Huang, H.-C. Chuang, S.-L. Lee, H.-C. Yang, C.-C. Chiou, H.-C. Chiu, D. Wang, S. K. Kulp, and C.-S. Chen Science Signaling (2013)
Antitumor effects of OSU-2S, a non-immunosuppressive analogue of FTY720, in hepatocellular carcinoma.
H. A. Omar, Y. C.-C. Chou, L. Berman-Booty, Y. Ma, J.-H. Hung, S. K. Kulp. T. Kogure, T. Patel, D. Wang, N. Muthsuamy, J. C. Byrd, and C.-S. Chen Hepatology (2011)

Updated 2018.03.21

Browser & IE Recommendations: 1024*768 / IE 8.0、Firefox 10.0

128, Academia Road Sec. 2, Nankang, Taipei 115, Taiwan Tel : 886-2-27855696 Fax : 886-2-27889759

Copyright © 2013.01 IBC, Academia Sinica. All rights reserved.    Terms of use